SAN CARLOS, Calif. – BioCardia®, Inc. [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, welcomes Krisztina Zsebo, Ph.D., a 31-year veteran of the biotech industry, to its Board of Directors following her election at BioCardia’s 2020 Annual Meeting of Stockholders in December 2020.

Dr. Zsebo has extensive biotechnology experience in discovery, development, and commercialization, having raised more than $200 million to support operations and having launched breakthrough technologies and products with total annual sales exceeding $3.5 billion. She was an integral member of the Amgen team that first cloned the molecule that would become Neupogen; identified the molecule and led the Amgen research team that developed Stemgen; and led Xenotech, a division of Cell Genysis, which developed Vectibix, a fully human antibody technology for colorectal cancer. In addition to her leadership and development experience, Dr. Zsebo has contributed to 113 biotechnology publications, has been awarded 34 composition, process and method patents, and has 26 patents pending. She earned her Ph.D. in biochemistry from the University of California, Berkeley.

Among her roles on the BioCardia Board of Directors, Dr. Zsebo is expected to serve as Chair of a Science and Technology Committee, with Simon H. Stertzer, M.D. She replaces Fernando L. Fernandez, whose term on BioCardia’s Board of Directors expired at BioCardia’s 2020 Annual Meeting of Stockholders in December. In addition, Richard C. Pfenniger, Jr. stepped down from BioCardia’s Board in January 2021.